Cytokeratin 5/6 Fingerprinting in HER2-positive Tumors Identifies a Poor Prognosis and Trastuzumab-Resistant Basal-Her2 Subtype of Breast Cancer

Oncotarget - United States
doi 10.18632/oncotarget.3106